{
    "nct_id": "NCT05477823",
    "official_title": "Pilot Study to Identify Radiogenomic Biomarkers to Predict Early Treatment Response to Androgen Deprivation Therapy and Radiation Therapy in High Risk Prostate Cancer",
    "inclusion_criteria": "* Age ≥ 18\n* Histologically confirmed adenocarcinoma of the prostate\n* Cancer classified as high-risk or very high-risk by National Comprehensive Cancer Network (NCCN) criteria: Grade group ≥4, PSA >20, or primary tumor stage ≥T3a\n* ECOG performance status 0-1\n* Agreed to undergo EBRT, high dose rate (HDR) brachytherapy boost, and 6-36 months of ADT as part of standard of care therapy prior to study enrollment\n* Able to undergo a HDR brachytherapy implant: Pre-radiation IPSS score ≤20 with or without medical management; prostate ≤60 cc as measured by MRI or ultrasound; no prior trans-urethral resection of prostate (TURP); and, median lobe extending into the bladder <1 cm\n* No prior or concurrent malignancy unless disease-free for at least 5 years\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Evidence of regional or distant metastatic disease on pre-treatment bone scan, pelvic MRI, and/or CT of the abdomen/pelvis\n* Prior pelvic radiation therapy",
    "miscellaneous_criteria": ""
}